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PREVALENCE OF SYNTHETIC CANNABINOIDS IN FORENSIC CASEWORK 
BASED ON DATA FROM THE DRUG ENFORCEMENT ADMINISTRATION’S 
NATIONAL FORENSIC LABORATORY INFORMATION SYSTEM 
 
JUDY VEIGA COSTA 
ABSTRACT 
 Synthetic Cannabinoids are among newly synthetized drugs that have become 
widely known throughout the United States and around the world. Originally, these 
compounds were used by researchers to isolate the medicinal effects of natural cannabis.  
Ultimately these compounds found their way into the illicit drug market as an alternative 
to marijuana. Unfortunately, the pharmacology of synthetic cannabinoids is not known in 
detail but it has been confirmed that they elicit stronger, more often times negative effects 
compared to natural cannabis. The use of these compounds have resulted in cases of 
overdose and even death.  
 The National Forensic Laboratory Information System (NFLIS) collects drug 
report information involving narcotics, stimulants, depressants, hallucinogens, cannabis, 
and emerging drugs such as anabolic steroids, phenethylamines, and synthetic 
cannabinoids, to name a few. They receive drug reports from forensic laboratories and 
perform statistical analysis to establish the prevalence of these drugs through out the 
United States. Specifically, the use of published NFLIS data sets from 2009-2013 and 
unpublished data set from 2013-2014 provided prevalence information from laboratories 
that have received synthetic cannabinoids in their forensic casework. The use of 
additional surveys and databases to supplement NFLIS data sets were used to better 
  vi 
understand which particular groups of people are most likely to consume synthetic 
cannabinoids and in what specific regions. Understanding how common the abuse of 
synthetic cannabinoids provides information on how best to control them and potentially 
prevent health risks associated with their use.  
 The prevalence of synthetic cannabinoid use has demonstrated an increasing-
decreasing-increasing pattern throughout the years. The specific synthetic cannabinoids 
that have been identified in drug cases have changed over time to bypass the drug control 
laws. The future prevalence of these drugs is uncertain but knowledge of current patterns 
may help us to understand the state of this issue and plan for the future cases our forensic 
drug chemistry laboratories will face.  
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1.0 INTRODUCTION 
 
1.1 Origin of Synthetic Cannabinoids 
 
Figure 1. Variety of synthetic cannabinoid packages from the Tarrant County Medical 
Examiner’s Office: Drug Chemistry Section. 
 
Synthetic cannabinoids are new psychoactive substances (NPS) similar to 
marijuana. Synthetic cannabinoids were first synthesized as early as the 1970’s through 
academic research centers and pharmaceutical industries in order to mimic the medicinal 
effects of cannabis and without the psychoactive effects
[1]
. However, the emergence of 
these drugs on the illicit drug market has become significant throughout the United 
States. The synthetic cannabinoid agonists are available as herbal packages marked as a 
“legal high”[1]. Names for these products include “Spice”, “K3”, “K2”, and “Dream”, 
however there are an extensive list of names, as shown in the Appendix A
[1]
. Some 
articles refer to all synthetic cannabinoids as “Spice” because of its common reference, 
which will be used throughout this paper. Spice is defined as a group of commercially 
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psychoactive drugs that can contain one or more synthetic cannabinoids, which is 
dissolved in a solvent and sprayed on an herbal substrate
[1]
. The solvent is then 
evaporated, dried, and packaged either as loose-leaf, pre-rolled, or powder form. More 
often, they are dissolved in a volatile solvent, such as ethanol or acetone, and then 
sprayed or otherwise mixed with an assortment of plant leaves, such as Indian Warrior, 
Lion’s Ear, Dog Rose and/or Marshmallow leaves, which are themselves reported to have 
psychotropic effects upon smoking
[1]
. Synthetic cannabinoids have also been identified in 
the liquids used for electronic cigarettes, along with other synthetic drugs such as Bath 
salts and psychedelics. 
A motive for users to obtain these drugs is to thwart positive toxicology results 
during drug testing as analytical methods are not available and/or implemented for all 
synthetic cannabinoids
[2]
. The dangers of the drug have not been entirely established. The 
effects of the synthetic cannabinoids can vary within a batch and between batches due to 
varying compounds and dose, which makes the toxicological analysis difficult
[2]
. Other 
psychotropic agents such as Kratom or Salvia divinorum may be added to enhance the 
product’s effects [3]. Additionally, with the rapid emergence of newer synthetic 
cannabinoids, the ability to control and prohibit these drugs becomes more difficult 
causing the prevalence of use to increase despite the adverse psychiatric effects and 
fatalities they may cause
[3]
. 
 Spice was manufactured in China as early as 2004 and sold over the internet, in 
head shops, gas stations, or convenience stores as herbal products with the unspecified 
active ingredient being synthetic cannabinoids agonists
[4]
. Packages were marketed as 
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potpourri or incense and labeled “Not for human consumption”, or “aromatherapy use 
only” [4]. A 3-gram package costs about 20-30 Euros or 30-40 US dollars[4]. It wasn’t until 
2008 when German scientists reported a significant increase in Spice use 
[3]
. Synthetic 
cannabinoids laced on plant material were first reported in the U.S. in December 2008, 
when a shipment of “Spice” was seized and analyzed by U.S. Customs and Border 
Protection (CBP) in Dayton, Ohio
[5]
.  
 The major categories of synthetic cannabinoids present in Spice are classic 
cannabinoids, cyclohexylphenols, and aminoalkylindoles
[3]
. There are seven major 
categories of synthetic cannabinoids that have been identified as of 2012: (1) 
naphthoylindoles (JWH-018 and JWH-073), (2) naphthylmethylindoles, (3) 
naphthoylpyrroles, (4) naphthylmethylindenes, (5) phenylacetylindoles (JWH-250), (6) 
cyclohexylphenols (CP47,497), and (7) classical cannabinoids (HU-210)
[6]
. Common 
compounds that have been identified are AM-, HU-, JWH-, RCS, XLR, and CP-. 
Compounds with the initials JWH were named after John W. Huffman, who was a 
medicinal chemist involved in evaluating the therapeutic potential of synthetic 
cannabinoids, based on the computational melding of aminoalkylindoles with THC
[4]
. 
Because the cannabinoid receptors were thought to have anti-nausea, appetite-
stimulating, and analgesic effects, scientists sought for a way to isolate those properties 
from the unwanted psychoactive effects of cannabis, which was found to be rather 
difficult
[2]
. The most common JWH compound is JWH-018 due its ease of synthesis and 
high pharmaceutical activity. Other known JWH compounds are JWH-122, JWH-210, 
JWH-081, JWH-073, JWH-250, and JWH-203
[2]
.  
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The HU-210 compound was developed by Raphael Mechoulam at the Hebrew 
University in the 1980s; it was discovered in January 2009 in herbal incense products in 
Wilmington, Ohio
[7]
. Cyclohexylphenol (CP-47,497) was synthesized by Charles Pfizer 
in the 1970’s and includes its C-8 homolog, cannabicyclohaxanol. Among the first 
compounds, HU and CP, were controlled by the DEA followed by the aminoalkylindole 
compounds which were synthesized to replace them. The indole-derived cannabinoids 
AM were synthesized by Alexandros Makriyannis
7]
. The JWH and AM compounds only 
differ by the addition of fluorine on the alkyl side chain
[8]
. The most common RCS 
compounds are RCS-4 and RCS-8 and are named after Research Chemical Suppliers as 
way to falsely market the compounds as research material
[7]
.  
Newer compounds consist of UR-144, XLR-11, PB-22, and SF-PB-22
[8]
. 
Compared with JWH and AM compounds, PB-22 has an additional 8-hydroxyquinoline 
structure modification
[8]
. One of the newer compounds, XLR-11, is a common synthetic 
cannabinoid agonist that has been recently detected in several fatalities, the first report 
originating in Japan in 2012
[9]
. This compound is a 5-fluorinated derivative of UR-144. 
The compound, UR-144, which has a tetramethylcyclopropyl structure modification was 
derived by Abbott Laboratories
[9]
. Its purpose was to become a selective full agonist to 
the CB2 receptors and have a lower infinity for the psychoactive CB1 receptors
[9]
. There 
are an extensive number of compounds that have been synthesized as seen in Appendix B 
that are not mentioned in this section.  
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1.2 Pharmacology 
Synthesized cannabinoids affect the cannabinoid receptors that are G-coupled 
receptors. Activation results in presynaptic hyperpolarization through changes in calcium 
influx and potassium efflux, resulting in neuronal hyperpolarization and a decrease in 
neurotransmitter release
[4,12]
. Neurotransmitters are chemicals that send signals across a 
synapse from one neuron to another. Hyperpolarization changes the cell’s membrane 
potential in which it inhibits the action potential by increasing the stimulus required to 
move the membrane potential to action potential threshold.  
The G-coupled receptors are named cannabinoid receptors (CBRs), CB1 and 
CB2. The CB1 receptors are expressed in the brain and regulate gamma aminobutyric 
acid (GABA) and glutamate neurotransmission
 [12]
. GABA is derived from the amino acid 
glutamate, and elicits relaxation, anti-anxiety, and anti-convulsive effects. GABA works 
with the central nervous system and is also responsible for regulating muscle tone. The 
CB2 receptors are expressed on immune cells and mediate immunosuppression. They 
also may play a role in pain and anti-inflammatory properties
[12]
.  
Marijuana’s active ingredient is Δ-9-tetrahydrocannabinol (THC) which exhibits 
partial agonistic activity at CB1 cannabinoid receptors in the central nervous system and 
CB2 in the periphery nervous system 
[12,13]
. In contrast, the synthesized cannabinoids are 
full agonists at high affinity at the CB1 and CB2 receptors. Physical effects of the CB1 
receptor include elevating a person’s mood but can also negatively cause anxiety and 
panic 
[12]
. The CB1 receptor is the main source of the psychoactive effects of the 
cannabinoids, which was the main reason for trying to modify cannabinoids to isolate 
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medicinal properties 
[12]
. CBRs are also complexed with other receptors, including opioid 
and dopamine receptors
[14]
. 
Synthetic cannabinoids are thought to be lipophilic and the parent compounds 
readily cross the blood-brain barrier and distribute to the CB1 receptors. THC has only 
one major psychoactive Phase 1 metabolite whereas synthetic cannabinoids have several 
different metabolic pathways, which results in many metabolites. “Earlier studies 
reported that several Phase 1 hydroxylated metabolites of AM2201, JWH-018, and JWH-
073 retain high affinity for CB1 receptors, often higher than THC” [15]. 
Routes of administration are commonly reported to be oral and inhalation but 
bioavailability is unknown. It is thought that the metabolic pathway involves hepatic 
cytochrome P450 oxidation followed by glucuronic acid conjugation.  
“Mechanistic studies have shown that selective inhibitors of CYP2C9 and CYP1A2 block 
oxidation of JWH-018 and AM-2201 in human liver microsomes, further demonstrating the 
importance of P450 isoforms in the detoxification of these compounds….individuals with certain 
allelic variants for these enzymes might be more likely to experience increased toxicity following 
the use of synthetic cannabinoids”[
14]
.  
Drug-drug interactions such as prescription drugs may affect the inhibition of these 
enzymes and thus create hazardous effects
[15]
.   
  Effects range from pleasant euphoria, calmness, relaxation to anxiety, psychosis, 
and modification in cognitive abilities such as with memory and attention
 [3,16,38]
. Physical 
effects range from sedation to agitation, sickness, hot flashes, burning eyes, dry mouth, 
pupil dilation, rapid heartbeat, tremors and palpitations. Perceptual changes include 
peripheral numbness, tingling, migratory flushing or cooling, and altered depth 
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perception
[3,16,38]
. Additionally, there may be a possible linkage between psychosis and 
synthetic cannabinoid use
[16]
.  A list of symptoms can be seen in Table 1 with symptoms 
broken down into categories of psychiatric, cardiovascular, neurological, and other 
symptoms.   
 Symptoms may start immediately or hours after use with variable duration. 
Withdrawal and dependence symptoms may be apparent with chronic use. These 
symptoms include headaches, anxiety/nervousness, coughing, insomnia/sleep 
disturbance, anger/irritability, impatience, difficulty concentrating, restlessness, nausea, 
and depression
[17,38]
.  
 Compared to cannabis, the synthetic cannabinoids are much more potent. They 
attach to the cannabinoid receptors as full agonists rather than partial agonists. Synthetic 
cannabinoids may also have longer half-lives based off their longer duration and effects. 
However, their effects have been reported to be slightly different from cannabis such as 
stimulating feeling of having energy, a greater high, and some negative effects.  
 
1.3 Toxicity 
 The potency of these drugs and their psychoactive affects make them addictive 
and hazardous, however toxicity of these drugs cannot be readily determined
[12]
. In a 
study involving 29 patients admitted to the emergency department in Germany, toxicity 
symptoms lasted 4-14 hours with a concentration ranged from 0.38-13 ng/mL of JWH-
018 in serum. Of these patients 40%  had one or more compounds in their systems. It is 
unclear how these cannabinoids affect the system individually or combined
[7]
. Khullar et 
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al reports a 20-year-old Hispanic man brought to 
the emergency department by the police in 
Florida. He appeared to have hallucinations and 
threatened to use a knife to harm his girlfriend. 
He appeared agitated, unable to keep still, 
inattentive, and shivering. Lorazepam and 
Haloperidol along with intravenous fluids were 
used for treatment. The patient was a previous 
user of amphetamines but most recently admitted 
to the use of marijuana and inhaling bath salts. 
The article emphasizes the similar effects 
synthetic marijuana can have from its natural 
counterpart, possibly confusing the two 
[18]
. 
However, synthetic marijuana poses a more 
dangerous risk. Case reports have identified 
injuries such as rhabdomyolysis, kidney failure, 
and respiratory depression from synthetic 
cannabinoid use. They have been linked to 
acute kidney injury even in patients without previous renal disease history. Other severe 
injuries include cardiac arrhythmias, myocardial infarctions, even seizures. Synthetic 
cannabinoid users can develop tolerance after only a few doses, causing them to have a 
greater chance of overdose from toxicity
[18,39]
.  
Table 1. Signs and Symptoms Associated 
with Synthetic Cannabinoids [16] 
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There were about 6 reports of fatalities in 2012 due to synthetic cannabinoid 
product use 
[19]
. Reports of two fatalities are discussed below based off of XLR-11 use. A 
29-yr-old female was found dead on the floor of her bedroom after consuming a 
packaged labeled “Black Dragon”. The decedent was a known user of synthetic 
cannabinoids and was reported to have symptoms of intoxication and agitation. 
Toxicological analysis found 1.4 ng/mL of XLR-11 in the peripheral blood, thus 
confirming the cause of death to be synthetic cannabinoid toxicity
[9]
. 
 Another case involved a 32-yr-old female who was found dead in the bedroom of 
a friend’s house. She was known for using heroin, methamphetamine, and synthetic 
cannabinoids. Internal examination at autopsy involved pulmonary edema and 
congestion, acute visceral congestion, and mild pulmonary anthrocosis (carbon 
pigments). Positive toxicological findings were found for naxolone, caffeine, and XLR-
11. Emergency personnel administered naxolone, which is why it appeared in the 
findings.  Due to the additional presumptive findings of caffeine, cause of death was 
deemed undetermined. The quantity of XLR-11 was 0.6 ng/mL
[9]
.  
 The XLR-11 compound was reported to be the cause of acute kidney injuries in 
four states. The decedents of these two cases had a concentration of 33 and 35 ng/mL 
respectively, with symptoms of nausea, vomiting, abdominal pain, and back pain. 
Compared with the clinical analyses, the post mortem cases had a significantly low XLR-
11 concentration. However, due to the other negative toxicological analysis as well as the 
lack of natural disease, the cause of death was attributed to XLR-11 toxicity 
[9]
.  
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 Due to the recent methods of identifying and quantifying synthetic cannabinoids 
in bodily fluids, Kronstrand et al conducted a toxicological analysis on case involving a 
17-year old male. The decedent was found dead outdoors after smoking an herbal product 
called “Smoke XXX” [2]. Cause of death was determined to be hypothermia, temperature 
being 6-8 °C during the night, due to the intoxication of the synthetic cannabinoids. His 
friend who had also smoked the material had gone inside after losing perception of touch 
in his hands. Similar symptoms may have occurred to the deceased, causing him to lose 
reaction to temperature. JWH-210 was detected in femoral blood with a concentration of 
12ng/g. The decedent had a low body index and internal examination found lung edema. 
Due to the findings, the manner of death was ruled to be an accident 
[2]
. Because of the 
varying dosages and the lack of homogeneity of synthetic cannabinoids when sprayed 
onto the herbal material, it is difficult to determine how severe these products may affect 
the user 
[2]
.  
 
 1.4 Purity of Synthetic Cannabinoids 
 Ginsburg et al analyzed the purity of synthetic cannabinoids in an experiment 
involving herbal products from three different suppliers. The purity of these herbal 
products poses a problem because there is no claim of purity by the suppliers nor is it 
certain whether or not these impurities may lead to the side effects and toxicity that is 
seen with these drugs. JWH-018 and JWH-073 of 98% purity was obtained as a reference 
standard to compare to the purity of the three different samples they obtained online, one 
from China and two domestic sources. The drug at a concentration of 1 mg/mL was 
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dissolved in methanol and diluted with mobile phase and injected into the HPLC. The 
scientists looked at color, texture and odor and found that some of the different 
compounds ranged from white to dark brown, as can be seen in Table 2. Textures tanged 
from fine powder to a chunky powder to a resin to a gel. There was an odor of 
naphthalene in some of the sources as well 
[20]
.  
 
Table 2. Drug characteristics of synthetic cannabinoids from various sources [20] 
 
 A sample chromatogram of six cannabinoids can be seen in Figure 2 using 50 
microliters of each sample containing 1000 ng/mL with the exception of delta-9-THC, 
which was at a concentration of 2000 ng/mL
 [20]
. The retention times of the eluents 
ranged from 17.5 minutes to 52.7 minutes. The RCS-4 compound eluted first followed by 
JWH-250, JWH-073, JWH-018, JWH-081, and delta-9-THC. Solutions of individual 
drugs were also injected and analyzed to determine any contamination. Preparation from 
all sources appeared to have one single peak, indicating its purity 
[20]
.  
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Figure 2. Total Ion Chromatograph (TIC) of the most common synthetic cannabinoids detected. [20] 
 
 The drug solutions from the various sources were prepared at a concentration of 
1000 ng/mL and the results of the purity were expressed a percentage of the expected 
concentration. Purity ranged from 75.3% to 91.4%. It was concluded that based on the 
high purity results, the toxicity may be unlikely due to impurities in the preparation of 
these synthetic cannabinoids. Impurities may be due to the addition of other chemical 
constituents in the herbal blends or due to the synthetic cannabinoids themselves, 
possibly a combination of both. There was no evidence of other additional compounds in 
any of the products obtained from their sources 
[20]
.   
Delving further into the psychoactivity of the herbal material alone, Dresden et al, 
analyzed several herbal blends and concluded psychoactive alkaloid ingredients were 
apparent such as betonicine, aporphine, leonurine, or nuciferine 
[21]
. The active 
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ingredients of these herbal blends continuously change within the same product, making 
the labeling of the composition of such products moot relatively quickly. This experiment 
involved more than 140 packets of herbal mixtures. Ethanol was added to 100mg of the 
mixtures, vortexed, centrifuged, and extracted. The samples were reconstituted with 100 
microliters of ethyl acetate and injected into the GC/MS at 1 microliter. Synthetic 
cannabinoid compounds that were identified were CP-47,497-C8, JWH-018, JWH-073, 
JWH-250 as well as O-desmethyltramadol which is a metabolite of the opioid tramadol. 
Components from the herbal mixtures were identified as fatty acids or nicotine, but 
nothing with psychoactive properties. In 44 samples, no active compounds were 
identified while in others the active ingredients identified were not listed 
[21]
.  
After the initial synthetic cannabinoids were put under control in Europe, the 
active compounds in these herbal products changed in order to change its legal status. 
CP-47,497-C8 compound was replaced by JWH-073 due to lack of control in Germany 
after 2009. Of 35 samples, 11 contained no synthetic cannabinoids, half contained only 
JWH-018 compounds and the other half contained CP-49,497-C8 compounds. After 
2009, 45 samples contained no synthetic cannabinoids and were reported to be sold to 
maintain profit, followed by 31 samples containing the newer JWH-073 compound. Out 
of the 45 samples containing no synthetic cannabinoids, 12 of those samples contained 
psychoactive ingredients such as harmine, harmaline, THC and cannabidiol, and O-
desmethyltramadol, which were declared as additive components
[21]
.  
 
 
 14 
1.5 Detection Methods for Synthetic Cannabinoids 
 Until recently, there have been no detection methods for synthetic cannabinoids 
due to the constant modifications of these structures. THC immunoassays do not cross-
react with synthetic cannabinoids, however, there has been a recent ELISA test that uses 
polyclonal antibodies to detect aminoalkylindole cannabinoids 
[4]
. Confirmatory testing 
involves liquid chromatography/tandem mass spectrometry (LC/MS/MS) and gas 
chromatrography/mass spectrometry (GC/MS). Urine samples have been analyzed by 
glucuronidase incubation and extracted via liquid-liquid or solid-phase extraction. Saliva 
and serum samples can also be analyzed as well 
[7]
. There are no definite guidelines as to 
which metabolites to measure, what their cutoffs should be, and there are no standardized 
quality control materials or proficiency tests. Too low of cutoffs may either indicate 
recent use or the slow release of cannabinoids from fat stores of a chronic user and too 
high of a cutoff may turn positive findings of cannabinoids as negative findings 
[7]
. 
In 2011, Kneisel et al developed a method involving the LC/MS/MS for the 
analysis of ten synthetic cannabinoids in human serum, which identified and quantified 
JWH-015, JWH-018, JWH-073, JWH-081, JWH-200, JWH-250, WIN 55,212-2 and 
methanandamide successfully. These scientists wanted to improve their analysis by 
expanding their experiment to 30 synthetic cannabinoids in human serum involving 
liquid-liquid extraction and LC/MS/MS.  Reference standards were obtained via Sigma-
Aldrich and Cayman Chemicals. The method proved to be successful for the 
quantification of 27 substances. The limits of detection ranged from 0.01 to 2.0 ng/mL, 
and the lower limits of quantification were in the range from 0.1 to 2.0 ng/mL. The 
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method was applied to 833 serum samples sent from psychiatric and rehab clinics as well 
as involved in criminal investigations. Synthetic cannabinoids were positive in 227 
samples, which accounted for 27% of all samples. The compounds identified were JWH-
018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-203, JWH-210, 
JWH-307, AM-2201 and RCS-4, the most common being JWH-210 (80%), JWH-122 
(63%) and AM-2201 (29%) 
[22]
.  
 Kronstrand et al, analyzed whole blood samples from cases involving synthetic 
cannabinoid use via LC/MS. Over 3000 cases were analyzed from recreational users as 
well as severe intoxication cases. Samples were prepared by adding JWH-018-D11 as an 
internal standard with 1g of whole blood. Calibrators involved concentrations of 0.05, 
0.1, 1.0, and 5.0 ng/g with quality control concentrations at 0.1 and 4.0 ng/g. Retention 
times for the 29 compounds to be detected ranged from 0.81 minutes to 5.90 minutes as 
can be seen in figure 3. Analytes are spread out over the chromatic range, however, some 
analytes did co-elute. Only AM-1241, JWH-147, JWH-015, and JWH-073 deviated from 
the target value for accuracy and JWH-398 for between-day precision. 28% of all 
samples were positive for one or more synthetic cannabinoid, the most common finding 
appearing to be the AM-2201 compound. 60% of the samples had a single finding of 
synthetic cannabinoids, while 27% had 2, 11% had 3, and 2% had 4 or more synthetic 
cannabinoids 
[2]
.   
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Figure 3.  Extracted and overlaid ion chromatograms for a 0.1-ng/g QC sample. Peak identification: 
1, AM-2233; 2, AM-1241; 3, AM-1220; 4, JWH-200; 5, WIN 55.212–2; 6, AM-694; 7, RCS-4-ortho; 8, 
AM-2201; 9, JWH-015; 10, RCS-4; 11, MAM-2201; 12, JWH-250; 13, JWH-073; 14, JWH-073-
methyl; 15, JWH-251; 16, JWH-203; 17, JWH-018-d11; 18, JWH-018; 19, JWH-081; 20, JWH-007; 
21, JWH-098; 22, JWH-122; 23, JWH-019; 24, RCS-8; 25, UR-144; 26, JWH-398; 27, JWH-210; 28, 
JWH-147; 29, JWH-020; 30, AB-001 [2] 
 
1.6 Case Reports of Synthetic Cannabinoids 
 The following are several accounts of synthetic cannabinoid intoxication from 
several articles emphasizing the health risks associated with use. One case was of a traffic 
accident involving a male driving a truck and a female in a car. The man had signs of 
bloodshot eyes, slurred speech, and a delayed reaction to instructions from the police 
officers that responded to the call. There was a marijuana-like odor in the car as well as 
on his breath. After colliding with the woman, the man started to drive away slowly until 
he was stopped. The man was arrested and evaluated by a Drug Recognition Expert 
(DRE).  The evaluation started about 105 minutes after the collision. His performance 
was very slow and lethargic, lacked balance, and lack of depth perception, among other 
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symptoms. He claimed to have smoked blueberry spice. Whole blood was collected for 
toxicological analysis and 1.34 ng/mL of XLR-11 was identified 
[23]
.  
 Two women, 20 and 22 years of age needed emergency treatment after taking a 
synthetic cannabinoid product called “Banana Cream Nuke” [24]. Initially, the women felt 
disoriented, not knowing where they were and subsequently called 911. The 22-year-old 
was anxious and had palpitations immediately after use, which subsided. A physical 
examination was unremarkable and she was discharged after being observed for an hour. 
The 20 year old also presented with anxiety and a psychotic feeling. Her heart rate was 
increased but everything else was unremarkable. JWH-018 and JWH-073 were identified 
in the product via GC/MS and HPLC/MS. It was reported that one the ingredients, 
passionflower, has psychotropic effects, specifically anxiolytic effects, which may have 
contributed to the symptoms the patients were experiencing 
[24]
. 
 Harris et al described a series of 6 case reports in which two patients; a 19-year-
old woman and a 19-year-old man experienced a single episode of seizures after synthetic 
cannabinoid use
 [12]
. Three patients experienced hallucinations, stating it felt as if they 
were “being stuck in multiple dreams with the inability to get out, and the act of being 
frightened and combative” [12]. All six patients except one experienced a quickened heart 
rate. These symptoms resolved themselves after a few hours of observation. One 
woman’s experience resulted in depression and had to be taken to the Mental Health ward 
upon admittance. Negative urine drug tests for cannabinoids were obtained for all but one 
who admitted he was a heavy cannabis user and a concentration of 184.7 ng/mL of THC 
was identified 
[12]
. “Variability in clinical presentation is unknown, but may be due to the 
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Spice compound used, the individual susceptibility to the drug effects, the dose, or it may 
be multifactorial” [12].  
 
1.7 Marijuana Origin and Properties 
Unlike synthetic cannabinoids, cannabis has been around for centuries. Cannabis 
was first used for medicinal purposes around 2737 B.C. The medicinal benefits were not 
deemed legitimate in the United States until 1851. However, the health risks of marijuana 
changed the status of this drug into a schedule 1 drug in 1942. The three main types of 
cannabis medicine are dronabinol, nabilone, and nabiximols, the latter is not FDA 
approved. The first two were used in 1985 for cancer patients in the treatment of nausea 
and vomiting following chemotherapy and was taken as a last resort. In 1992, dronabinol 
was used to treat anorexia for patients with acquired immune deficiencies. Nabiximols is 
being used for symptomatic relief for patients with multiple sclerosis and may become 
FDA approved following trials in the United States. In 1999, the Institute of Medicine 
made several recommendations for the safety of cannabis use such as knowing the 
pharmacological effects and risks, an effective delivery system for medical cannabis, and 
clinical trials to better understand the medicinal properties of cannabis 
[25]
.  
Natural cannabis contains over 400 compounds of over 60 cannabinoids, the most 
potent psychoactive ingredient being Δ9 tetrahydrocannabinol but may also contain 
cannabinol and cannabidiol. The past 20 years has changed the concentration of THC in 
marijuana from 10 mg in the 1960’s/70’s to 150 mg of THC, thus changing the 
knowledge that has been obtained from smaller doses. About 50% of THC of the 
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marijuana is inhaled into the lungs, to the bloodstream, and into the brain within seconds 
of smoking. Cannabis is lipid-soluble and will accumulate in the fatty tissues for several 
days before it is released back into other body compartments. The tissue elimination half-
life of THC ranges from 7 days to 30 days 
[13]
.  
Cannabis affects almost every body system. It combines many of the properties of 
alcohol, tranquillizers, opiates and hallucinogens with its anxiolytic, sedative, analgesic, 
psychedelic effects. Additionally, its toxicity is extremely low as there have been no 
reported deaths directly due to cannabis use. Majority of recreational users use cannabis 
strictly for pleasure purposes. However, cannabis can also produce negative reactions, 
including severe anxiety and panic, paranoia and psychosis. These reactions are dose-
related and more common in first-time users, anxious and psychologically vulnerable 
individuals 
[13,25]
.  
The high can be induced with doses of THC as low as 2.5 mg in herbal cigarette 
and includes a feeling of intoxication, with decreased anxiety, alertness, depression and 
tension and increased sociability
 [25]
. Things like color, music, and emotions are 
significantly heightened. Spatial perception is distorted and time perception is impaired. 
Hallucinations may occur with high doses. Reaction times become delayed, there’s a lack 
of physical balance, as well as defects in short term memory, attention, and completing 
complex tasks. Driving is also said to be impaired with cannabis use. These impairments 
can last for many weeks, months or even years after cessation of cannabis use. Whether 
or not this becomes permanent during chronic use is still not clear 
[25]
.  
As far as health risks go for cannabis users, cannabinoids are reported to produce 
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a dose-related tachycardia, which may reach rates of up to 160 beats/minute or more. But 
more importantly, it is actually the tar from a cannabis cigarette that contains higher 
concentrations of benzanthracenes and benzpyrenes, both of which are carcinogens, that 
is detrimental as compared to tobacco smoke. “It has been estimated that smoking a 
cannabis cigarette results in approximately a five-fold greater increase in 
carboxyhemoglobin concentration, a three-fold greater amount of tar inhaled and 
retention in the respiratory tract of one-third more tar than smoking a tobacco 
cigarette”[25]. Chronic cannabis smoking is also associated with bronchitis and 
emphysema 
[25]
. 
 
 
1.8. Marijuana Vs. Synthetic Marijuana 
Based on Figure 4, the speed of onset of synthetic marijuana vs. natural marijuana 
are about the same
[28]
. Sixty percent of a sample of 898 people reported the speed of 
onset upon synthetic or natural marijuana occurred within one hour. For others, it took 
longer than an hour. The peak effect takes longer for natural marijuana use than synthetic, 
which is understandable because of the partial agonistic effects of natural marijuana. 
Natural marijuana was reported by a little over 40% of individuals as having a peak effect 
over an hour, which was slightly more than the 38% who reported the peak effect within 
an hour. Synthetic marijuana is a full agonist, thus creating stronger effects a in a shorter 
time. Approximately 55% of synthetic marijuana users reported the peak effect to occur 
within an hour. Lastly, the duration of peak effects last longer in synthetic marijuana than 
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natural marijuana. About 65% of 
synthetic marijuana users reported 
the peak effect to last an hour 
compared to only about 25% natural 
marijuana users 
[28]
.  
The effects of synthetic 
marijuana and natural marijuana 
appear to be slightly different as 
seen in Table 3
 [28]
. Synthetic 
marijuana has a slight increase in 
hang over effects, paranoia, lung 
effects, and negative effects while 
high. Individuals self-rated their 
experience of synthetic marijuana 
versus natural marijuana from 1-10; 
1 being weak and 10 being strong. 
Natural marijuana was significantly 
more pleasurable and an increase in 
appetite. Similar qualities included 
relaxation effects, cost, functionality, addictiveness, memory impairments, and 
consistency of product 
[28]
. 
Figure 4. A. Speed of Onset (Minutes), B. Time to 
peak effect (Minutes), C. Duration of Peak Effects 
(hours) 
 C. Duration of peak effect of natural marijuana 
vs. synthetic marijuana [28]. 
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Table 3. Comparisons between synthetic and natural marijuana effects from self- rated evaluations 
[28]. 
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2.0 HYPOTHESIS 
Due to the previously published information provided by the NFLIS datasets, the 
new data sets would show a continued use of the synthetic cannabinoids as well use of 
structurally modified newer synthetic cannabinoids. For example, many JWH compounds 
had a greater prevalence than XLR-11 but as XLR-11 gained its popularity, JWH use 
reduced significantly due changes in legislation. This shows that there will be a continued 
trend of a constant change of which new synthetic cannabinoid becomes more common 
in order to bypass drug control laws. Additionally, the number of people who use 
synthetic cannabinoids is predicted to vary through the years, alternating in increasing 
and decreasing patterns. There are numerous factors contributing to the prevalence of 
synthetic cannabinoid use including its appeal to cannabis users as an alternative drug to 
abuse as well as its ability to potentially be undetected by traditional drug testing 
methodologies. 
Epidemiological research of drugs of abuse that evaluate forensic casework data 
sets alongside research of emerging drugs of abuse is one of the research priorities for the 
field of forensic toxicology 
[41]
. This research on the prevalence of synthetic cannabinoids 
is fundamental to advancing our knowledge base of these compounds in the field of 
forensic toxicology as it provides relevant and timely information on the numerous 
variations of these drugs, whether the drug bans are effective, and what the forensic 
laboratories should be looking for regarding drug and toxicology cases. Forensic 
laboratories can then use this data on prevalence to supplement information from clinical 
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and forensic case reports in order to assess the dangers that synthetic cannabinoids may 
have in a given populated area 
[41]
.  
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3.0 MATERIALS AND METHODS 
3.1 DATABASES 
3.1.1 National Forensic Laboratory Information System Data Query System 
The National Forensic Laboratory Information System Data Query System is a 
part of the Drug Enforcement Administration Office of Diversion Control, which collects 
data from drug-related cases of the federal, state, and local level
 [29]
. All 50 state crime 
laboratories are involved in this secure database as well as 272 out of 302 of state and 
local forensic laboratories. Only participating laboratories and DEA approved 
laboratories are able to submit data to the Data Query System and is free of cost. As of 
December 2010, laboratories representing over 92% of the National drug caseload 
participated in NFLIS, with about 88% of the National caseload reported for each data 
reference period. There have been changes regarding representation and statistics for drug 
reports. The first change involves volunteer laboratories, defined as laboratories that are 
not official forensic laboratories, which are used as a way to accurately represent the 
prevalence of drug use 
[29]
.  
The second change is that estimates are based on cases and items submitted to 
laboratories during the data reference period and that have been analyzed within three 
months of the end of the data reference period. The third change involves the accounting 
of multiple drugs per item. For each item (or exhibit) analyzed by a laboratory in the 
NFLIS program, up to three drugs can be reported to NFLIS and counted in the 
estimation process. The database consists of up to 13 million cases and 20 million items 
spanning over 13 years of collection.  It organizes information on the types, prevalence, 
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and location of emerging drugs. This information can be helpful for drug control and 
drug scheduling policies 
[29]
.  
 
3.1.1.1 Statistical Methodology  
Two variables were used for laboratory representation: (1) type of laboratory and 
(2) determination of “certainty” laboratory status. Certainty laboratories are large 
laboratories that are deemed critically important for the calculation of reliable estimates. 
These certainty laboratories are based on size, region, geographical location, and other 
special considerations 
[30]
.  
Two weights were created: one for estimating cases and one for estimating drug 
reports. The weight used for case estimation is based on the caseload for every laboratory 
in the NFLIS population, and the weight used for drug report estimation is based on the 
item load for every laboratory in the NFLIS population. For reporting laboratories, the 
caseload and item load used in weighting are the reported totals. For nonreporting 
laboratories, the caseload and item load used in weighting are obtained from an updated 
laboratory survey administered in 2013 
[30]
.  
Each weight has two components, the design weight and the nonresponse 
adjustment factor, the product of which is the final weight used in estimation. After 
imputation, the final item weight is based on the item count, and the final case weight is 
based on the case count of each laboratory or laboratory system. The final weights are 
used to calculate national and regional estimates. The first component, the design weight, 
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is based on the proportion of the caseload and item load of the NFLIS database
 
represented by the individual laboratory or laboratory system. Nonreporting and reporting 
(sampled) laboratories are calculated separately using the following formula:  
Design Weighti = A/(B × Case [item] Count for Laboratory or Laboratory System i),  
 
where i = number count of laboratory or laboratory system; A = sum of the case (item) 
counts for all of the laboratories and laboratory systems (sampled and nonsampled) 
within a specific stratum, excluding certainty strata and the volunteer stratum; and B = 
number of sampled laboratories and laboratory systems within the same stratum, 
excluding certainty strata and the volunteer stratum 
[30]
. 
The nonresponse adjustment factor adjusts the weights of the reporting and 
sampled laboratories to account for the non-reporting and sampled laboratories which is 
calculated as follows: 
NRj =C/D 
Where j= stratum; C=  number of sampled laboratories and laboratory systems in the 
stratum, excluding the volunteer stratum; and   D=  number of laboratories and 
laboratory systems in the stratum that were both sampled and reporting 
[30]
.    
Monthly data is computed differently from data that may not be reported within a 
given  month. The formula for calculating monthly case counts is seen below 
 28 
where RL = set of all nonmissing months in laboratory 
L , cL,m = case count for laboratory L in month m , and c.,m = 
mean case counts for all laboratories reporting complete data. 
For the missing monthly data, the formula below is used:  
where RL = set of all nonmissing months in laboratory L, 
iL,m = item count for laboratory L in month m, and cL,m = case 
count for laboratory L in month m 
[30]
. 
The weighting formulas are what make the estimates more precise by assigning 
large weights to small laboratories and small weights to large laboratories. Under 
National Estimates Based on All Reports (NEAR), the sampling fraction equals the 
number of sampled laboratories divided by the sum of the number of sampled 
laboratories and the number of nonreporting, unsampled laboratories. Volunteer 
laboratories are not included in the sampling fraction calculation 
[30]
.  
Statistical analysis are performed across years are using the prior-year 
comparisons technique and long-term trends technique if applicable. The prior year 
comparisons compare national and regional estimates from the current year and the 
previous year. Long-term trends compare the national and regional estimates from the 
span of several years 
[30]
. 
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3.1.1.2 Benefits and Limitations of NFLIS 
One of the benefits of the NFLIS database is that it provides information on the 
prevalence and type of controlled substances. It features certain characteristics of the 
drug such as quantity, purity, and drug combinations. The database also identifies 
emerging drugs and the variety of controlled and noncontrolled substances at the 
national, state, and local levels. Most importantly, it supplements information from other 
databases such as System to Receive Information from Drug Evidence (STRIDE), 
National Survey of Drug Use and Health, and Monitoring the Future studies. The NFLIS 
Data Query System is being improved upon by adding a new interagency exchange 
forum that will allow the DEA, forensic laboratories, and other members of the drug 
control community to post and respond to current information 
[27]
. 
There are a few limitations in interpreting data from the NFLIS. The information 
involves drugs that have undergone a complete analysis through the laboratories. Any 
drugs that were seized and were not analyzed are not represented in the dataset. As 
laboratories have different policies in what they analyze; some drugs may be submitted 
but only certain items may be analyzed. This could be dependent on whether the court 
dismissed the criminal case or there is no defendant for the case. Additionally, 
laboratories may keep varying records regarding the quantity of drugs submitted, thus the 
amount of submissions may only be an estimate and not an accurate account. State and 
local policies in terms of police efforts and prosecution of certain drugs may affect what 
is submitted and what is not 
[27]
.  
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During the computation of statistics, there is a suppression of unreliable estimates 
so drugs may not be adequately represented 
[27]. “For some drugs, such as cannabis/THC 
and cocaine, thousands of reports occur annually, allowing for reliable national 
prevalence estimates to be computed. For other drugs, reliable and precise estimates 
cannot be computed because of a combination of low report counts and substantial 
variability in report counts between laboratories” [27]. Drug estimates with a relative 
standard error of less than 50% are suppressed and not shown in the NFLIS data tables
27]
.  
3.1.1.3 NFLIS Datasets 
 The datasets from the NFLIS include the 2009-2010 report, 2010-2013 report, the 
2014 midyear report, as well as an unpublished data set for January 2013 to January 2014 
(Table 8). Information from the published reports includes national and regional 
estimates as well as national counts of exposure calls to poison control centers regarding 
synthetic cannabinoids. Additionally, they include the prevalence of the various 
cannabinoid compounds identified as well newly reported emerging synthetic 
cannabinoids. The unpublished dataset is broken up into three calendar periods: the first 
half of 2013, the second half 2013, and the first half of 2014. National counts were 
reported for the types of synthetic cannabinoid that were identified; however these counts 
are raw data that have not been calculated using the following methodology in section 
2.1.1.1 and acts a supplement for the 2014 midyear report. 
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Drug Name 
 2013   Jan-
June  
 2013    
Jul-Dec  
 2014   
Jan-June  
XLR11  11,273  6,466  6,602  
UR-144  1,243  690  512  
AM-2201  884  305  201  
PB-22  668  1,035  1,342  
5F-PB-22  544  1,330  758  
AKB48 N-(5-fluoropentyl)  417  427  199  
AKB48  285  69  106  
JWH-018 (AM-678)  173  152  93  
JWH-122  125  54  59  
JWH-250  118  43  39  
JWH-210  111  33  44  
STS-135  84  29  4  
MAM-2201  64  80  57  
JWH-081  55  14  12  
RCS-4  25  7  8  
JWH-203  21  3  23  
JWH-022  20      
AM-694  18     2  
A-796,260  16      
JWH-019  14  *  6  
AM-2233  10  20  4  
CB-13  8     1  
JWH-018 Adamantyl Carboxamide  5      
JWH-073  4  6  14  
RCS-8  2      
AM-1248 *    2  
Synthetic Cannabinoid  832  730  1,184  
Synthetic Cannabinoid (Naphthoylindoles)  95  46  84  
AB-FUBINACA  26   2,389   4,326  
AB-PINACA  25  937  2,232  
5-Chloro-UR-144  16  5  85  
Synthetic Cannabinoid (Phenylacetylindoles)  15  10   
EAM-2201  12  8  57  
URB754  12  7  3  
A-834,735  4     2  
URB-602  3      
AM-679  2      
CP 47,497-C8-Homolog  1  1   
HU-210  1  1  2  
HU-211  1      
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HU-308  1     1  
UR-144 N-(5-Chloropentyl) Analog  1  2  2  
URB597  1     1  
AM-2201 N-(4-fluoropentyl)  1      
UR-144 N-heptyl analog  1     1  
4-fluoro AB-PINACA      4  
5F-AB-PINACA   36  193  
5-fluoro ABICA      35  
5-fluoro NPB-22      7  
5-FLUORO-ADBICA   6  18  
5-MAPB      2  
AB-001      1  
AB-CHMINACA      324  
ADB-FUBINACA      161  
ADB-PINACA   67  11  
AKB48 N-(4-fluorobenzyl)      1  
AM2201 Benzimidazole analog   *  77  
BB-22    46  27  
FDU-PB-22      40  
FUB-144      6  
FUB-AMB      9  
FUB-PB-22   7  124  
JWH-007      1  
JWH-200   1  1  
NM2201      67  
SDB-006      1  
Synthetic Cannabinoid (Adamantoylindoles)   * * 
Synthetic Cannabinoid (Benzoylindoles)     * 
Synthetic Cannabinoid (Cyclopropanoylindoles)   128  136  
Synthetic Cannabinoid (Quinolinylindolecarboxylates)   280 * 
THJ 2201      117  
XLR11 N-(4-fluoropentyl) isomer   9  1  
Total Estimates Presented  17,237   15,480   19,432  
Grand Total**  17,242   15,750   19,841  
        
*Estimates supressed due to high relative standard error 
(RSE)       
**Includes suppressed estimates       
    
 
Table 4. Unpublished dataset of synthetic cannabinoid drug reports from January 2013-June 2014. 
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3.1.2. Other Databases 
Other data on the prevalence of synthetic cannabinoid use was obtained from the 
American Association of Poison Control Centers, which manages the National Poison 
Data System. The system collects information on exposures of poisons and drugs that are 
submitted to their centers. Exposures are defined as being around or coming into contact 
with a substance through ingestion, or inhalation, skin or eye absorbance, but it does not 
necessarily mean the person who had been using was poisoned or overdosed. However, 
any information obtained from the 55 poison centers can provide additional information 
on synthetic cannabinoids that may be impacting society.  
Further information can be found with the European Monitoring Centre for Drugs 
and Drug Addiction
[10]
. Located in Lisbon, Portugal, it is the equivalent of the NFLIS in 
that it provides information for emerging drugs to prevent drug use and drug addiction 
and additionally to formulate European drug laws and policies
[10]
. 
Lastly, Monitoring the Future, located at the University of Michigan, collect 
information using surveys in schools. Recently, they were used to show the prevalence of 
synthetic cannabinoid use in high school and middle schoolers and how it impacts 
students of different levels of education
[31]
. The Monitoring the Future Study is funded by 
a series of investigator-initiated competing research grants from the National Institute on 
Drug Abuse, which is a part of the National Institutes of Health
[31]
. Other surveys from 
journal articles are also discussed in this paper as supplemental information.  
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Many databases were used to compare prevalence data of natural and synthetic 
marijuana use. These databases may target specific groups of people on a global, 
national, state, or school level. Although surveys are not always fully representative, the 
data collected about the prevalence of drug use and abuse can inform people of the risks 
of use due its production and marketing around the world. Drug bans can then put in 
place that are based off reports received from laboratories, poison control centers, or 
other databases. The main source of information, however, comes from the NFLIS 
datasets of synthetic cannabinoid reports from 2009-2013 as well as the unpublished 
dataset (Table 8) for 2013-to June 2014, provided by the Drug Enforcement 
Administration for the purpose of this study. For 2015 data, the information is based off 
the drug reports from the American Association of Poison Control Centers 
[36]
.  
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4.0 RESULTS/DISCUSSION 
4.1 European Prevalence of Synthetic Cannabinoids 
Although the use of synthetic cannabinoid may have started in Europe, prevalence 
in Europe has been low compared to the United States with only 29 reports of the use of 
synthetic cannabinoids based on surveys
 [10]
. Authorities have seized bulk powders of 
JWH-018, AM-2201, AM-6527, XLR-11, and AKB48 from countries such as Denmark, 
Finland, Spain, and France in 2012 and 2013
 [10]
. Large quantities of these bulk powders 
in Netherland and Belgium indicate an Internet retail trade within the European Union. 
The United Kingdom (England and Wales) reported 0.2% of adults ranging from 16-64 
years of age used synthetic cannabinoids in 2010/2011, and 0.1% in 2011/2012. In Spain, 
prevalence of use was around 1% for students aged 14-18 years out of a total of 27,503 
students surveyed. 1.0% indicated last year prevalence while 0.6% indicated last month 
prevalence, indicating a decrease in use. Germany had a higher prevalence use of 7% 
from 2009-2012, with the exception of 9% in 2010 for reported lifetime levels of use. 
The percentages represented students of ages 15-18 years old. However, the surveys 
claim to be inadequately represented because there is a higher chance of use of people 
who have experience cannabis previously as well as particular groups such as clubbers 
and Internet users 
[10]
.  
Another survey conducted by the Global Drug Survey was conducted between 
November and December of 2011 in order to determine the correlation of natural 
marijuana use with synthetic cannabinoids
 [28]
. Over 15,000 responses were received from 
around the world, primarily in the UK and US. Other locations included Canada, 
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Australia, and Ireland. 16.8% of the participants reported using synthetic cannabinoids. 
Of these, 40.6% reported used in the last 12 months. Participants were primarily white 
males with a median age of 23 years and a mean age of 25.3 years. 66.6% are employed, 
53.3% were currently studying, and 36% had obtained a university degree. Most of the 
participants either lived with their parents, with friends, or with a partner. 49.3% were 
from the United States, 26.6% were from the United Kingdom, 5.6% reported from 
Australia, 3.5% from New Zealand, 1.8% from Canada and Finland, and 1.3% from 
Hungary. This indicates that that the United States and the United Kingdom are among 
the countries where synthetic cannabinoid use is prevalent. Synthetic cannabinoid users 
also reported using other drugs as can be seen in Table 9, the most prevalent being 
alcohol, natural cannabis, tobacco and energy drinks in the last month. One third of these 
participants were also daily tobacco smokers. Of the recent synthetic cannabis users, 
99.3% of them reported also using natural cannabis. 88% of users who smoked natural as 
well as synthetic marijuana admitted to using in the last month, with 24.6% using daily. 
This clearly signifies that the users of synthetic cannabis will have most likely actively 
used natural cannabis before. When comparing synthetic cannabis use to natural cannabis 
use, 80% used natural cannabis more so than synthetic cannabis. 8.2% used synthetic 
cannabis more so than natural cannabis and 0.84% reported daily use of both types of 
cannabis 
[28]
.  
“Although the pattern of use is reported in this study and the comparatively low reported 
demand for treatment may reassure policy makers and health providers it is too early to 
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confidently predict that its currently low level of uptake and perceived attractiveness will limit its 
wider use and the experience of harms.”[28] 
 
4.2 Synthetic Cannabinoid Drug Scheduling 
 In 2009, parts of Europe such as Austria, Germany, France, Luxembourg, Poland, 
Lithuania, Sweden, UK and Estonia placed all products in the Narcotics Law, prohibiting 
all products from being sold in head shops and online stores
[10]
. In 2011, the United 
States placed five synthetic cannabinoids, JWH-018, JWH-073, JWH-200, CP-47,497, 
and (C8)-CP-47,497 on the Schedule 1 list of the Controlled Substances Act (CSA), 
which states that there is a high potential for abuse and no medicinal properties for these 
synthetic cannabinoids
[1]
. The concern about this prohibition is the appearance of newly 
synthesized cannabinoids as well as the modification of products in order to bypass the 
law.  
 The Controlled Substance Analogue Enforcement Act of 1986, also known as the 
Federal Analogue Act, allows many synthetic drugs to be treated as controlled substances 
if they are proven to be chemically and/or pharmacologically similar to a Schedule I or 
Schedule II controlled substance
[5]
. A recent act, The Synthetic Drug Abuse Prevention 
Act, is part of the FDA Safety and Innovation Act of 2012, signed into law by President 
Obama.  The law permanently places 26 types of synthetic cannabinoids and cathinones 
into Schedule I of the Controlled Substances Act (CSA).  Fifteen of these drugs are 
synthetic cannabinoids. Newer compounds such as UR-144, XLR11, AKB48, PB-22, 5F-
PB-22, AB-FUBINACA, ADB-PINACA, and numerous other SCs varying only by slight 
modifications to their chemical structure, are included in the ban 
[5]
. AB-FUBINACA and 
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ADB-PINACA as well as THJ-2201, were not encountered until late 2013 to early 2014 
and have caused multiple deaths and overdoses 
[11]
. These three synthetic cannabinoids 
were recently placed as a temporary Schedule 1 drug in December 2014. The additional 
benefit of the Synthetic Drug Abuse Prevention Act also doubled the maximum period of 
time that the Drug Enforcement Administration (DEA) can schedule substances under its 
emergency scheduling authority, from 18 to 36 months.
[11]  
At the state level, at least 43 states have taken action to control one or more 
synthetic cannabinoids as seen in Table 5. As of 2013, Massachusetts and New 
Hampshire were currently pending. However, in 2014, Massachusetts recently passed a 
ban making Spice products illegal, including any synthetic cannabinoid derivative and in 
February 2015, New Hampshire followed in the prohibition of these products as well
[8]
.  
 
 
Table 5. State controls of synthetic cannabinoids [8].  
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4.3 Prevalence of Synthetic Cannabinoid Compounds 
The acts to control synthetic cannabinoid products do not necessarily stop all 
manufacturing processes. Psyche Deli, a manufacturer of Spice in the UK grew by 
1300% from 2006 to 2007 while manufacturers in the US made sales of $6,000/day. To 
avoid the ban, they claimed that their strategy is to load their products with another 
synthetic cannabinoid compound to bypass the legislation 
[7]
.  
The compound JWH-018 was most prevalent in the first half of 2010 with 
approximately 86% and decreased in that same year with 59% of the synthetic 
cannabinoids detected. By 2013, only 1% of these compounds detected were JWH-018 
compounds, indicating the constant modifications of these synthetic compounds to evade 
legislation
[8]
. The most common synthetic cannabinoid compounds to be detected 
throughout October 2011 to January 2013 were JWH-210, UR-144, AM694, JWH-122, 
MAM-2201, JWH-018, and AM-2201
[2]
. AM-2201 appeared in less than 1% of all drug 
reports in late 2010 but gradually increased to about 50% in 2012 and decreased 
significantly to 5% in early 2013. XLR-11 appeared to be the most prevalent in early 
2013 comprising 65% of cases with almost little to no detection during the previous 
years
[2]
. Additionally, newer compounds such as RCS-8 and STS-135 began to show 
some prevalence. Table 6 shows the newly emerging synthetic cannabinoids that are now 
becoming more prevalent than the previously known compounds. There is an 
increasingly expanding array of synthetic drugs available
[8]
. Fifty-one new synthetic 
cannabinoids were identified in 2012, compared to just two in 2009
[5]
. Many more are 
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being identified and as the law starts to ban identified old synthetic cannabinoids, 
compounds such as A-834,735 or STS-135 fly under the radar. 
 
Table 6. Newly reported emerging synthetic cannabinoids in 2013[8]. 
 
Figure 5 shows a compilation of data from the NFLIS reports of 2009 to the midyear 
report of 2014 as well as information from the NFLIS unpublished data. The transition of 
the prevalence of some of the synthetic cannabinoids is apparent with the most current 
popular compound. XLR-11 was barely common with less than 2,000 reports in 2012, 
which then hit about 11,000 reports in 2013. The JWH-018, which was the most common 
with less than 2,000 reports in 2010 and disappeared with less than 100 reports by the 
first half of 2014. During a certain year or period, a compound becomes initially popular 
and then starts to decrease in prevalence or becomes progressively popular as changes 
our made to the composition of the herbal products. 
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Figure 5. Compilation of data from the NFLIS unpublished data set and NFLIS published datasets 
from 2009-2014. 
 
4.4 Prevalence of Marijuana  
 The use of marijuana has been by far greater than the use of synthetic 
cannabinoids. But as these new synthetic compounds continue to be developed, will it 
surpass the prevalence of natural marijuana? From 1996, a survey involving 3075 
university students from 10 UK universities found that about 60% had some experience 
with cannabis; nearly 25% had tried it more than once or twice and 20% of students 
reported regular use. It was most common for cannabis users to start at school and that 
30-40% of 15- to 16-year-olds have tried it 
[13]
. 
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 Based off the National Survey on Drug Use and Health, as seen in Table 7, about 
44% of individuals 12 and older have experienced either marijuana or hashish during 
their lifetime. 51% of individuals with life-time use are from age 18 to 25 years old; this 
age range is significant for past year and past month use as it regards the greatest 
percentage of use compared to other ages 
[26]
.   
         
Table 7. Prevalence of Marijuana/Hashish in 2013 based on the National Survey of Drug Use and 
Health (NIH) [26]. 
In 2013, a total of 1,540,647 drug reports were identified by the State and local 
forensic laboratories in the United States. The synthetic cannabinoid XLR11 (19,243 
reports) was also included in the top 25 drugs. Cannabis/THC was the most frequently 
identified drug (469,581 reports) in 2013, followed by cocaine (240,810 reports), 
methamphetamine (206,784 reports), and heroin (151,690 reports). Nationwide, 
cannabis/THC reports showed an S-shaped trend in that they decreased from 2001-2004, 
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slightly increased from 2004-2009, and decreased from 2009-2013. Cannabis was more 
prevalent in the Midwest region followed by the south region of the United States as seen 
in Figure 6. However, there is clearly a slight decrease throughout the years. From 2012 
to 2013, THC/Cannabis use decreased from 513,095 reports to 469,581 reports 
[27]
. 
 
Figure 6. Regional trends in cannabis/THC reported per 100,000 persons aged 15 or older, January 
2001-December 2013 [27] 
 
4.5 Legalization of Marijuana 
 
For the last 40 years, the legalization of marijuana has been debated around the 
world
[42]
. In 1996 California passed a citizen-initiated referendum, Proposition 215, that 
allowed the medical use of cannabis for conditions such as nausea, weight loss, muscle 
spasms, and pain
[43]
. Marijuana is currently legal for medical use in 23 states and 
recreational marijuana is legal in Colorado and Washington as of 2012. In the 2014 
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elections, Alaska, Oregon, and Washington D.C. joined the legalization states. On a 
global level, Australia decriminalized marijuana in some territories while the Netherlands 
legalized marijuana. Many organizations have different perspectives on how much 
impact marijuana has on society compared to other drugs. Some consider marijuana a 
safe drug and that possession in small amounts should be allowable for medicinal use. 
The laws that are in place against marijuana are excessiveness and unnecessary because 
of marijuana’s low toxicity compared to more hazardous drugs like heroin and cocaine. 
They also believe that the costs to society associated with marijuana use are far less than 
that of alcohol and tobacco use. Another theory is that if marijuana is legalized and 
deemed safer than other drugs, there may be a switch from more hazardous drugs
[42]
. 
On the contrary, marijuana is just as hazardous as any other drug and even shares 
many features with other illicit drugs
[42]
. Withdrawal symptoms from marijuana is linked 
to a corticotropin releasing factor that is the same chemical that is linked to anxiety and 
stress during opiate, alcohol, and cocaine withdrawal. The metabolite, THC, stimulates 
the release of dopamine which is the same chemical that is released that reinforced 
dependence on other drugs. Lastly, mental problems may be linked to marijuana use. 
Legalizing marijuana may very well cause an increase in the use and therefore an 
increase in health costs as well as social and economic costs. “Legalization of Marijuana 
could result in advertising campaigns for its use, some of which might be directed 
towards adolescents. Control measures to prevent advertising to young people, as recent 
experience demonstrates, may be difficult to implement”[43]. Once marijuana is 
allowable, the use of this drug at an early age may cause a significant impact in starting 
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use and future use. For example, opiate prescriptions for pain relief has far greater side 
effects and people are more susceptible to addiction upon use as opposed to marijuana 
use 
[42]
. 
 So far, the legalization or decriminalization of marijuana in the U.S. has not seen 
a significant increase in marijuana use or marijuana related harm. Hall et al concluded 
that the trend of marijuana use due to legalization is not predictable as of yet because it’s 
still a fresh implementation
 [43]
. The prevalence of marijuana use can go in either 
direction, the more favorable would be an increased use in lieu of more harmful drugs 
such as its alternative counterpart, synthetic cannabinoids 
[42]
.
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4.6 Demographic Analysis of Synthetic Cannabinoids 
 
Table 8. Drug use prevalence among recent users of synthetic marijuana [28] 
Vandrey et al conducted an Internet survey in 2011 using surveymonkey.com
 [17]
. 
168 were eligible to complete the survey involving synthetic cannabinoid use. The survey 
represented 13 different countries and 42 US states. They were mostly single, white 
males who completed the survey, having a high school education. Half of them had a 
college degree. Half of them were employed while 28% were students. Majority of them 
were users of alcohol and cannabis as well as other drugs such as opioids and stimulants. 
Spice use occurred typically alone or in small groups with motivations of curiosity, they 
liked the effects, for relaxation, and to avoid cannabis detection for drug urinalysis 
testing. For the participants who perceived safety in synthetic cannabinoid use, 88% had 
the knowledge that chemical compounds were added to a plant to induce intoxication, 
while 11% thought the products only contained natural herbs and spices 
[17]
.  
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Based on the calls received from the American Association of Poison Control 
Centers, the highest percentage of use of synthetic cannabinoids involved students aged 
13-19 years
 [31]
. The Drug Abuse Warning Network confirmed that young adults from 
ages 18-20 years were at a higher risk of poisoning from synthetic cannabinoids than 
other age groups. Monitoring the Future performs studies every year on the behaviors and 
attitudes of approximately 50,000 students from Grades 8, 10, and 12. Figure 7 and 8 
depicts the prevalence of marijuana use and synthetic marijuana use, respectively, among 
teens throughout 1974-2014. Marijuana use was prevalent among high school seniors 
from as early as 1974 and continues to be the most common age at which marijuana is 
used, followed closely by 10
th
 graders starting around the 1990s, due to ease of 
availability and accessibility. The percentage of students who used initially was 
approximately 40% and ranged from about 50% down to about 20%. Trends in drug use 
seem to increase and decrease throughout the years. The risk assessment in using 
regularly is more prevalent in 8
th
 graders, however with a slight decrease throughout the 
recent years.  A significant number of students of all grades disapproved in the regular 
use of marijuana 
[31]
. 
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Figure 7.  Use of Marijuana in schools as surveyed by Monitoring the Future [31] 
  
 Compared with natural marijuana, synthetic marijuana use was nonexistent 
among students until about 2012 as shown in Figure 8. High school seniors also showed 
greater prevalence of synthetic marijuana use than the 8
th
 or 10
th
 graders. Marijuana users 
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were at less than half of all students surveyed; synthetic marijuana users were only at a 
mere 10% for high school seniors and this age group continues to be at risk for multiple 
uses. No data was found for disapproval or availability but based on the availability 
found; it may be similarly accessible as natural marijuana 
[31]
.  
"Most students still do not recognize synthetic marijuana as a dangerous class of drugs, 
although the proportion of 12th-graders reporting it as dangerous to use did rise significantly in 
2014," Johnston said. "Efforts at the federal and state levels to close down the sale of these 
substances may be having an effect." [31] 
Additionally in 2012, high school seniors specifically were surveyed for the use of a 
broad number of drugs. In Figure 9, Marijuana is still the most common drug used among 
high school seniors with 36.4%, followed by synthetic marijuana with 11.3% and other 
drugs such as hallucinations, Salvia, MDMA, and cocaine are being used at a much lower 
percentage. There was a significant decrease in synthetic marijuana use to only 6% in 
2014 
[32]
. This data supports the hypothesis in that upon introduction of the new synthetic 
cannabinoids, initial curiosity may have increased the prevalence of use but continued 
use of synthetic cannabinoids have varied. This trend is similar to the prevalence of 
marijuana use and because of the similar effects that synthetic marijuana has to natural 
marijuana, it is more likely that synthetic marijuana will be most prevalent among 
previous cannabis users.  
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Figure 8. Use of Synthetic Marijuana in schools as surveyed by Monitoring the Future. [31] 
 
     
Figure 9. Prevalence of use of illicit drugs by high school seniors surveyed by Monitoring the Future 
[31] 
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 Palamar et al used Monitoring the Future surveys from 2011-2013 in order to 
better inform researchers, policymakers, and educators about which teens and young 
adults are at higher risk of potential synthetic marijuana use. Even though there is a 
decline in use, Palamar et al claims that these surveys tell people very little due to a small 
sample base. These scientists focus more on demographic information such as age, sex, 
race, population density, parental income, and previous drug use. It was concluded that 1 
out of 10 students surveyed have used synthetic marijuana in the last 12 months with 
3.2% using frequently. Synthetic marijuana use is reported to be prevalent among white 
males, who have a higher income, who go out more frequently, and have used previous 
drugs such as alcohol, cigarettes, marijuana, or other illicit drugs. Lifetime alcohol use as 
well as previous smoking experience doubled the odds for synthetic cannabinoid use and 
the more often students went out for the evening correlated with the increased odds of 
use
[32]
.  
“There is no evidence suggesting use of novel psychoactive drugs such as synthetic 
cannabinoids as an alternative to other illicit drugs. However, since use is extremely rare among 
non-drug users, it is possible that many students who have already used drugs try using synthetic 
cannabinoids as an alternative to other illicit drugs. Such “legal” highs are often used because use 
is less likely to result in arrest; they may be more available, less costly, and risk of harm or stigma 
is perceived to be lower.”[32]  
Students who had lower odds of using were reported to be of racial minority, highly 
religious, live with two parents, or had parents with high academic achievement. 
Research is still needed to determine whether the use of marijuana’s legality strongly 
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correlates with the introduction of synthetic cannabinoid use as a replacement or if 
previous marijuana users try the synthetic alternative just for experimental purposes 
[32]
.  
On a collegiate level, there have been reported uses of K2/Spice in college 
students in the southeast region of the United States with 8.5% reporting in 2011, 
followed by a decrease of 2.3% in 2013. Studies show that marijuana use is prevalent 
among the single, members of sororities and fraternities, high sensation seekers, same 
could be said for people who use synthetic cannabinoids. Specifically, a study was 
performed in 11 colleges in North Carolina and Virginia with 3,146 participants
 [33]
. The 
demographics of the prevalence of synthetic cannabinoids users are consistent with 
Palamar’s research in that white males with previous drug history, nonreligious, and a 
higher income were most likely to use synthetic cannabinoids. 7.6% of college students at 
entry (Fall 2010), meaning during their first year, reported lifetime use of synthetic 
cannabinoids, which decreased to 5.8% in the Spring of 2011, then to only 1.0%. Motives 
for this decrease claim to be due to maturation and possibly the change in policies for 
synthetic cannabinoid products, thus decreasing its availability. 65.8% of the college 
students who reported lifetime use at college entry had used in the past 6 months. 6.6% of 
first year students tried synthetic cannabinoids for the first time during college. 17% of 
users who first tried synthetic cannabinoids in their first year of college became lifetime 
users by Fall 2013 
[33]
.  
Furthermore, researchers recently reported that 4.5% of urine specimens collected 
from 5,946 U.S. athletes tested positive for synthetic cannabinoids, the highest of all drug 
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classes detected
 [34]
. In an article focusing on synthetic cannabinoid use in athletes; 5,946 
athletes samples were analyzed. 266 of the samples were positive for JWH-018 and/or 
JWH-073. Half contained JWH-018 while the other half contained JWH-073. Only 1% of 
samples contained both compounds. “The detection rate in the current study of 5,946 
athletes was 4.5%, which is much higher than the <0.03% reported earlier and makes 
synthetic cannabinoids among the most detected of all drug classes in athletes in our 
laboratory” [34]. Metabolites detected for the parent JWH-018 were JWH-18-N-pentanoic 
acid and JWH-018-N-(-5-OH-pentyl). For JWH-073, JWH-073-N-butanoic acid was the 
most commonly detected metabolite. Other studies, as stated in the article, reports that 
these parent compounds have been detected in 18% and 20.3% of samples 
[34]
. Synthetic 
cannabinoid use also has spiked among military personnel, and the Armed Forces are 
currently conducting a study to determine the prevalence of synthetic cannabinoid use 
within the military 
[37]
.  
 
4.7 NFLIS Data Results 
As previously stated, on the national level, the National Forensic Laboratory 
Information System (NFLIS) database collects information of drug identification and 
drug cases received by Federal, State, and local forensic laboratories. In 2010, there were 
approximately 2,977 reports of synthetic cannabinoids in comparison to only 27 reports 
during 2009, the common compounds being JWH-018. Most of the reports from 2010 
came from the Midwest followed by the South. As seen in Table 9, approximately 87% 
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of the cases involves JWH-018 compounds in 2009 which declined to 63% in 2010. 
Instead there was an increase in variations of JWH compounds from 0.00% 
[35]
.  
The NFLIS data set reveals that from 2010-2013, 83,217 reports involving 
synthetic cannabinoids were received, significantly increasing from just 469 at the 
beginning of 2010 to 23,123 in total for that year. The number of reports peaked in 2012 
and decreased to 17,241 reports by 2013. The most common reported synthetic 
cannabinoids were JWH compounds in 2010 followed by AM compounds in 2012 and 
XLR compounds in 2013. Information from Federal laboratories and Customs and Border 
Protection (CBP) Laboratories had a total of 24,992 drug reports in the first half of 2013, 
with 365 reports involving synthetic cannabinoids. 120 of those reports involved XLR-11 
compounds, and 76 reports involved AM-2201 compounds 
[8]
.  
NFLIS obtained data from the AAPCC Database as can be seen in Figure 10 and 
Figure 11 depicting the number of exposure calls received by month from 2010-2013
 [8]
. 
As previously mentioned, exposures do not necessarily mean that the person who had 
been using was poisoned by the substance or had overdosed, just that they had come into 
contact with the substance. Figure 10 shows a gradual increase from January 2010, 
initially starting at just 24 reports. This increased significantly in March of 2010 and 
continued to increase by November 2010. With a slight dip, reports totaled as high as 634 
by June 2011. Figure 11 includes the trends of years 2012 and 2013 
[8]
. During the first 
half of 2010, there was an initial count of 649 reports, which significantly increased to 
almost 4,000 reports in the second half of 2011 and started to decline during the first half 
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of 2012. The last report from early 2013 had about 1,461 reports, which was an increase 
from the initial report back in 2010. Though the reports have declined significantly, there 
is still evidence of significant use 
[8]
. 
 
Figure 10. National counts of exposure calls of synthetic cannabinoids to poison control centers by 
month from January 2010-June 2011 [35] 
 
 
Figure 11. National semiannual counts of synthetic cannabinoid exposure mentions to poison control 
centers from Jan 2010-June 2013 [8]. 
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Figure 12. A graph of the exposure calls of synthetic cannabinoids from 2010-2015 [36]. 
 
The unpublished data set that was received from NFLIS shows the different types 
of synthetic cannabinoids depicted as well the number of reports associated with those 
specific compounds. An estimated total of 17, 237 synthetic cannabinoid reports were 
received from January to June 2013, 15,480 synthetic cannabinoid reports received from 
July to December 2013, and 19,432 reports from January to June 2014. This shows a 
significant increase in 2014 after a slight dip in the second half of 2013. The most 
common synthetic cannabinoids across the 2 years was XLR-11, although with a 
decrease from 11,273 reports to 6,602 reports. UR-144, AM-2201, PB-22, and 5F-PB-22 
followed in prevalence also decreasing, with the exception of PB-22, which increased 
from 668 to 1,342 reports. The most common synthetic cannabinoid as of 2014 was 
XLR-11 followed by AB-FUBINACA with 4,326 reports, and AB-PINACA with 2,232 
reports. It can be noted that the synthetic cannabinoids that were once common has 
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reduced significantly in prevalence and that there may be significant increase in synthetic 
cannabinoid compounds that are less prevalent or unknown.  
An updated version of the synthetic cannabinoid reports for this year can be found 
on the AAPCC’s website as seen in Figure 12, which depicts the trend of exposure calls 
from 2010 to May of 2015
 [36]
. The numbers from Figure 13 differ slightly from the 
NFLIS reports due to updates and it also represents calls received just for information 
about synthetic cannabinoids. There were 112 calls concerning Spice in 2009 and 2,915 
in 2010 Between January 2011 and April 2012 there have been 11,561 calls, clearly 
indicating a rapid increase. The reports involving synthetic cannabinoids in 2011 was 
almost 7,000, though it decreased in half by 2015
[36]
. The NFLIS and AAPCC reports are 
consistent with its decline in 2013 but further information of AAPCC indicates a slight 
increase in 2014 followed by a slight decrease in 2015. Specifically by month this year, 
the prevalence of synthetic cannabinoids increased dramatically in April of 2015 with 
1,135 reports compared to the 269 in the previous month. In late April 2015, the 
American Association of Poison Control Centers issued a warning against the use of 
synthetic marijuana due to the 330% increase from January 2015, declaring that it is 
significantly different from natural marijuana and can cause life-threatening effects 
[36,40]
. 
From January 1
st
 to May 27
th
, 2015, the Poison Control Center has reported over 3,500 
reports for the use of synthetic marijuana in total 
[36]
.                                   
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Figure 13. Number of Cases of synthetic cannabinoid exposure from 2011-2015 and by month in 2015 
by the AAPCC Poison Center [36]. 
 
On the State level, a total of 32 states reported synthetic cannabinoids during 
2010
[8]
. Kansas, Louisiana, and North Dakota were the three states that experienced the 
most reports of 200 or more. Seven Midwest states had between 100 and 199 reports. 
These states proceeded to control synthetic cannabinoids within 2010 and 2011 after 
these numerous reports. By 2011, 40 states were represented as reporting synthetic 
cannabinoids in the first half of the year. At least thirteen states had over 200 reports 
while 9 states had between 100 and 199
[35]
. By 2013, there was an increase of 44 states 
reporting synthetic cannabinoids, with 20 states having over 200 reports. As seen in 
Figure 14, the south and Midwest regions remains as the location where the most 
prevalent use of synthetic cannabinoids is seen
[8]
.  
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Figure 14. Synthetic Cannabinoid Reports at the State Level, 2010, 2011, 2013 [8,35] 
 
 A compilation of the data from NFLIS information on regional prevalence of 
marijuana and several synthetic cannabinoids indicate that the prevalence of marijuana is 
still more significant even with the emergence of synthetic cannabinoids as shown in 
Figure 15. The most common synthetic cannabinoids listed are XLR-11, AB-
FUBINACA, AB-PINACA, and PB22 as being in the top 25 most identified drug within 
the NFLIS data system. 
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Figure 15. Regional prevalence of marijuana and several common synthetic cannabinoids (2014). 
 
The compound, XLR-11 is the only synthetic cannabinoids that reached 5,000 reports on 
a national level compared to the 240,000 reports on cannabis, which is 4800% greater. 
This figure also supports the fact that the South and the Midwest regions have the most 
occurrence of natural and synthetic marijuana related cases.  
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5.0 CONCLUSION 
 The prevalence of synthetic cannabinoid use has experienced a level of increase 
and decrease throughout the years.  There was a spike in 2011 and a dramatic increase in 
April 2015 as reported by the AAPCC. The reason for the alternate increasing and 
decreasing pattern could be due to the emergence of newer synthetic cannabinoids that 
are being synthesized in order to circumvent legislation when the older synthetic 
cannabinoids become banned. Throughout the years, there will be the possibility of rare 
synthetic cannabinoid compounds becoming more popular and still newer, unknown 
compounds that will be identified. The NFLIS datasets as well as the supplemental 
information of prevalence among specific groups of people indicate that synthetic 
cannabinoids will continue to have a significant presence in forensic casework. Also, the 
lack of scientific research and public awareness about the risks of synthetic cannabinoids, 
they will continue to be used and particularly by those who have already experienced the 
effects of natural cannabis.  
“So far little is known about metabolism and toxicology of these synthetic 
cannabinoid compounds. The health risks and carcinogenic potential caused by inhaling 
smoke containing these substances in not evaluated yet” [21]. If more information can be 
publicized of the negative effects of synthetic cannabinoids as compared to natural 
cannabis, it may be possible that there will be a reduction in the use of the drug. Surveys 
from users of both types of cannabis have confirmed that synthetic cannabinoids have a 
stronger and more negative effect. However, the benefit of using synthetic cannabinoids 
is the potential lack of detection during urine drug testing and seems to be the primary 
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reason of use. Synthetic cannabinoids may pose an even greater danger to users; it has 
been detected alone or in combination with drugs such as ecstasy and in some herbal 
cannabis in an attempt to strengthen the effects of the weak high from natural cannabis. 
Additionally, synthetic cannabinoids have been detected in electronic liquid cigarettes 
[10]
. The pace at which these synthetic cannabinoids are being made is unprecedented and 
the prevalence of certain types of synthetic cannabinoid compounds will constantly 
change.  
5.1 Future Research 
In the future, epidemiological research on synthetic cannabinoid use and reports 
from NFLIS and AAPCC should be closely monitored to determine the prevalence of the 
different types of synthetic cannabinoid compounds. The comparison of newer synthetic 
cannabinoids versus older ones and the drug control laws associated with these findings 
will confirm that the trend of synthetic cannabinoid will continue to change.  New 
datasets may give a more solid answer of whether the prevalence of emerging synthetic 
cannabinoids will prevail at the same rate or whether the appeal of an alternative to 
marijuana will begin to decline as more states legalize natural marijuana. 
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APPENDIX 
A. Street and Commercial Names for Synthetic Cannabinoids 
Products 
 
Albino Rhino Buds Genie Space Truckin' 
Aroma 
Armageddon 
Aztec Gold Gorilla Spice 
Barely legal Herb Dream Spice Arctic Synergy 
Black Mamba Herbal incense Spice Tropical Synergy 
Bliss Ice Bud Extra Cold Spice Diamond 
Bombay Blue K2 Spice Gold 
Caneff 5 star K3 Spice Gold Spirit 
Chillin XXX 
Cloud 9 K3 Legal Spice Silver 
D-Raw Kronic Spicey XXX 
Dark Matter 
Demon Krypto Buds SpiceWorld420 
Dream 
Magic 
Mad Hatter Spice99 (Ultra) 
Everlast Mojo Spike99 
Ex-ses (Platinum) 
Moon Rocks 
Mr. Nice Guy Smoke 
Experience: Chill Pep Spice Splice Platinum 
Experience: Ignite Red Magic Star Fire 
Experience: Red Ball Sence Syn 
Fake marijuana Skunk Yucatan Fire 
Fake Weed Smoke Zohai 
Fusion Solar Flare Zohai SX 
Galaxy Space 
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